TR200100234T2 - Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. - Google Patents
Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması.Info
- Publication number
- TR200100234T2 TR200100234T2 TR2001/00234T TR200100234T TR200100234T2 TR 200100234 T2 TR200100234 T2 TR 200100234T2 TR 2001/00234 T TR2001/00234 T TR 2001/00234T TR 200100234 T TR200100234 T TR 200100234T TR 200100234 T2 TR200100234 T2 TR 200100234T2
- Authority
- TR
- Turkey
- Prior art keywords
- sulfamate
- biogenic estrogen
- substitution therapy
- hormone substitution
- sulfamates
- Prior art date
Links
- 230000000035 biogenic effect Effects 0.000 title abstract 3
- 229940011871 estrogen Drugs 0.000 title abstract 3
- 239000000262 estrogen Substances 0.000 title abstract 3
- 229940088597 hormone Drugs 0.000 title abstract 2
- 239000005556 hormone Substances 0.000 title abstract 2
- 238000006467 substitution reaction Methods 0.000 title abstract 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 abstract 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 229920013685 Estron Polymers 0.000 abstract 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 abstract 1
- VGHIBOFCBWMZNZ-ZXXIGWHRSA-N NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 VGHIBOFCBWMZNZ-ZXXIGWHRSA-N 0.000 abstract 1
- YXYXCSOJKUAPJI-ZBRFXRBCSA-N [(8r,9s,13s,14s,17s)-17-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] sulfamate Chemical compound NS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 YXYXCSOJKUAPJI-ZBRFXRBCSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 abstract 1
- 229960001348 estriol Drugs 0.000 abstract 1
- 229960003399 estrone Drugs 0.000 abstract 1
- -1 estronsulfamate Chemical compound 0.000 abstract 1
- 239000007943 implant Substances 0.000 abstract 1
- 239000000583 progesterone congener Substances 0.000 abstract 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Biyojen estrojensülfamatlarin hormon substitusyon terapisinde (HRT) oral, kesintili uygulanmasinda kullanimi açiklanmaktadir. Kesintili verme 2-40 günlük araliklarla gerçeklestirilmektedir. Ek olarak gestajenlerin de, tercihen sürekli biçimde bir implantat veya intraoterin bir serbest birakma sistemi seklinde (IUD) uygulanmasi öngörülmüstür. Biyojen estrojensülfamat olarak estronsülfamat, estradiyolsülfamat, estriyolsülfamat veya asil zincirinde 7 adede kadar C atomu bulunan estronun, estradiyolün veya estriyolün N-asilsülfamati veya bu etki maddelerinden 2 veya daha fazlasinin bir kombinezonu kullanilmaktadir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19834931A DE19834931A1 (de) | 1998-07-28 | 1998-07-28 | Verwendung von biogenen Estrogenen zur Hormonsubstitutionstherapie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200100234T2 true TR200100234T2 (tr) | 2001-06-21 |
Family
ID=7876248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/00234T TR200100234T2 (tr) | 1998-07-28 | 1999-05-13 | Biyojen estrojensülfamatların hormon sübstitüsyon terapisinde kullanılması. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US7053077B1 (tr) |
| EP (1) | EP1100509B1 (tr) |
| JP (1) | JP4891479B2 (tr) |
| KR (1) | KR20010072082A (tr) |
| CN (1) | CN1311683A (tr) |
| AP (1) | AP2001002054A0 (tr) |
| AR (1) | AR016502A1 (tr) |
| AT (1) | ATE292468T1 (tr) |
| AU (1) | AU766019B2 (tr) |
| BG (1) | BG105171A (tr) |
| BR (1) | BR9912466A (tr) |
| CA (1) | CA2338558A1 (tr) |
| CO (1) | CO5261567A1 (tr) |
| DE (2) | DE19834931A1 (tr) |
| EA (1) | EA003371B1 (tr) |
| EE (1) | EE200100053A (tr) |
| HK (1) | HK1040192A1 (tr) |
| HU (1) | HUP0102913A3 (tr) |
| IL (1) | IL141081A0 (tr) |
| IS (1) | IS5819A (tr) |
| MX (1) | MXPA01000548A (tr) |
| NO (1) | NO20010468L (tr) |
| NZ (1) | NZ509521A (tr) |
| PL (1) | PL345588A1 (tr) |
| SK (1) | SK1292001A3 (tr) |
| TR (1) | TR200100234T2 (tr) |
| WO (1) | WO2000006175A1 (tr) |
| ZA (1) | ZA200100743B (tr) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1406634A1 (en) * | 2001-07-13 | 2004-04-14 | Schering Aktiengesellschaft | Combination of drospirenone and an estrogen sulphamate for hrt |
| US8026229B2 (en) | 2001-08-13 | 2011-09-27 | Sterix Limited | Antitumor-active 2-alkoxyestradiol sulfamates |
| US8282612B1 (en) | 2008-03-07 | 2012-10-09 | Denise H. Miller | Methods and devices for intrauterine absorption |
| RS62297B1 (sr) | 2011-11-23 | 2021-09-30 | Therapeuticsmd Inc | Prirodne kombinovane hormonske supstitucione formulacije i terapije |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2647379A1 (en) * | 2012-04-05 | 2013-10-09 | PregLem S.A. | Combined use of a steroid sulfatase inhibitor for the treatment of endometriosis |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US9078786B1 (en) | 2012-10-19 | 2015-07-14 | Denise H. Miller | Methods and devices for collecting body fluids |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| RU2016143081A (ru) | 2014-05-22 | 2018-06-26 | Терапьютиксмд, Инк. | Натуральные комбинированные гормонозаместительные составы и терапии |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
| CN116392450B (zh) * | 2022-09-07 | 2025-07-01 | 江苏集萃新型药物制剂技术研究所有限公司 | 含雌激素的皮下植入物及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5314694A (en) * | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
| AU7075594A (en) * | 1993-06-29 | 1995-01-24 | Leiras Oy | Pack for use in, and method of hormonal replacement therapy |
| DE4429397C2 (de) * | 1994-08-09 | 2003-11-20 | Jenapharm Gmbh | Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| DE4429398C2 (de) * | 1994-08-09 | 1997-09-11 | Jenapharm Gmbh | Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Kontrazeption |
| DE4429374C1 (de) | 1994-08-12 | 1996-02-01 | Jenapharm Gmbh | Pharmazeutische Präparate zur Kontrazeption/Hormonsubstitution mit biogener Estrogenkomponente |
| DE19610635A1 (de) * | 1996-03-11 | 1997-09-18 | Schering Ag | Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie |
| TW448049B (en) * | 1997-03-05 | 2001-08-01 | Akzo Nobel Nv | Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis |
| JP2002520346A (ja) * | 1998-07-17 | 2002-07-09 | ファルマシア・アンド・アップジョン・カンパニー | 避妊用皮下メドロキシプロゲステロンアセタート |
-
1998
- 1998-07-28 DE DE19834931A patent/DE19834931A1/de not_active Withdrawn
-
1999
- 1999-05-13 EP EP99936276A patent/EP1100509B1/de not_active Expired - Lifetime
- 1999-05-13 CN CN99809213A patent/CN1311683A/zh active Pending
- 1999-05-13 EE EEP200100053A patent/EE200100053A/xx unknown
- 1999-05-13 US US09/744,574 patent/US7053077B1/en not_active Expired - Fee Related
- 1999-05-13 WO PCT/DE1999/001496 patent/WO2000006175A1/de not_active Ceased
- 1999-05-13 AU AU51481/99A patent/AU766019B2/en not_active Ceased
- 1999-05-13 CA CA002338558A patent/CA2338558A1/en not_active Abandoned
- 1999-05-13 IL IL14108199A patent/IL141081A0/xx unknown
- 1999-05-13 NZ NZ509521A patent/NZ509521A/en unknown
- 1999-05-13 HK HK02101596.4A patent/HK1040192A1/zh unknown
- 1999-05-13 KR KR1020017001165A patent/KR20010072082A/ko not_active Withdrawn
- 1999-05-13 AP APAP/P/2001/002054A patent/AP2001002054A0/en unknown
- 1999-05-13 BR BR9912466-1A patent/BR9912466A/pt not_active IP Right Cessation
- 1999-05-13 MX MXPA01000548A patent/MXPA01000548A/es unknown
- 1999-05-13 TR TR2001/00234T patent/TR200100234T2/tr unknown
- 1999-05-13 JP JP2000562029A patent/JP4891479B2/ja not_active Expired - Fee Related
- 1999-05-13 AT AT99936276T patent/ATE292468T1/de not_active IP Right Cessation
- 1999-05-13 HU HU0102913A patent/HUP0102913A3/hu unknown
- 1999-05-13 PL PL99345588A patent/PL345588A1/xx unknown
- 1999-05-13 EA EA200100108A patent/EA003371B1/ru not_active IP Right Cessation
- 1999-05-13 DE DE59911879T patent/DE59911879D1/de not_active Expired - Lifetime
- 1999-05-13 SK SK129-2001A patent/SK1292001A3/sk unknown
- 1999-07-26 CO CO99046902A patent/CO5261567A1/es not_active Application Discontinuation
- 1999-07-27 AR ARP990103678A patent/AR016502A1/es not_active Application Discontinuation
-
2001
- 2001-01-19 IS IS5819A patent/IS5819A/is unknown
- 2001-01-23 BG BG105171A patent/BG105171A/bg unknown
- 2001-01-25 ZA ZA200100743A patent/ZA200100743B/en unknown
- 2001-01-26 NO NO20010468A patent/NO20010468L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200100743B (en) | 2002-05-08 |
| PL345588A1 (en) | 2001-12-17 |
| AU5148199A (en) | 2000-02-21 |
| NZ509521A (en) | 2003-11-28 |
| JP2002521452A (ja) | 2002-07-16 |
| WO2000006175A1 (de) | 2000-02-10 |
| CA2338558A1 (en) | 2000-02-10 |
| JP4891479B2 (ja) | 2012-03-07 |
| US7053077B1 (en) | 2006-05-30 |
| IS5819A (is) | 2001-01-19 |
| BG105171A (bg) | 2001-07-31 |
| DE19834931A1 (de) | 2000-02-24 |
| NO20010468D0 (no) | 2001-01-26 |
| AP2001002054A0 (en) | 2001-03-31 |
| KR20010072082A (ko) | 2001-07-31 |
| SK1292001A3 (en) | 2001-07-10 |
| ATE292468T1 (de) | 2005-04-15 |
| CN1311683A (zh) | 2001-09-05 |
| AU766019B2 (en) | 2003-10-09 |
| EP1100509B1 (de) | 2005-04-06 |
| AR016502A1 (es) | 2001-07-04 |
| HK1040192A1 (zh) | 2002-05-31 |
| HUP0102913A3 (en) | 2002-03-28 |
| IL141081A0 (en) | 2002-02-10 |
| MXPA01000548A (es) | 2002-04-08 |
| EA003371B1 (ru) | 2003-04-24 |
| BR9912466A (pt) | 2001-04-17 |
| NO20010468L (no) | 2001-03-27 |
| CO5261567A1 (es) | 2003-03-31 |
| DE59911879D1 (de) | 2005-05-12 |
| EA200100108A1 (ru) | 2001-12-24 |
| HUP0102913A2 (hu) | 2002-01-28 |
| EP1100509A1 (de) | 2001-05-23 |
| EE200100053A (et) | 2002-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200100108A1 (ru) | Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии | |
| UA41401C2 (uk) | Фармацевтичний контрацептивний комбінований препарат | |
| BR9709934A (pt) | Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga | |
| KR960704553A (ko) | 적어도 하나의 프로게스토겐과 적어도 하나의 에스트로겐을 함유하는 대용요법용 제제(preparation for substitution therapy containing at least one progestogen and at least one estrogen) | |
| ES2087964T3 (es) | Contraceptivos orales bajos en estrogenos. | |
| TR200200406T2 (tr) | Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması | |
| DK0836506T3 (da) | Transdermalt plaster til indgivelse af 17-deacetyl norgestimat alene eller i kombination med et østrogen | |
| YU14502A (sh) | Farmaceutska kombinacija etinilestradiola i drospirenona za primenu kao kontraceptivnog sredstva | |
| BG101553A (en) | Progesterone antagonist and antiestrogenous active compounds of general application for female contraceptives | |
| ATE248853T1 (de) | Pharmazeutische zusammensetzungen mit estra-1,3, 5(10)-trien-derivaten | |
| BR9710566A (pt) | M-todo anticoncepcional monof sico e um kit compreendendo uma combina-Æo de uma progestina e estrog-nio | |
| WO2000042942A3 (en) | Buccal drug delivery system for use in male contraception | |
| AR049112A1 (es) | Composiciones, metodos y kit, para el tratamiento de trastorno disforico premenstrual | |
| YU57201A (sh) | 16-hidroksiestratrieni kao selektivno aktivni estrogeni | |
| BR9915215A (pt) | Composição farmacêutica para liberação modificada de sensibilizador de insulina | |
| PL356847A1 (en) | Hormonal composition based on a progesterone and an oestrogen and use thereof | |
| ATE278406T1 (de) | Orales contrazeptivum | |
| UA81387C2 (en) | Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive | |
| PT1007052E (pt) | Combinacoes de progestinas de crescimento do endometrico e progestinas de atropia do endometrio com estrogenios, em contracepcao oral | |
| HUP9901474A2 (hu) | Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához | |
| TH55261A (th) | การใช้ไบโอเจนิคอีสโตรเจนซัลฟาเมทในการรักษาการทดแทนฮอร์โมน | |
| Leoprapai | Impact of the introduction of NORPLANT implants into the national family planning program of Thailand | |
| JO2213B1 (en) | A pharmaceutical composition for use as a contraceptive method | |
| RU97110374A (ru) | Способ повышения приживляемости эмбрионов у овцематок-реципиентов введением прогестерона | |
| RU2006126632A (ru) | Стероиды, имеющие смешанный андрогенный и прогрестагенный профиль |